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A
 
BSTRACT
Background:
 
Clinical and experimental studies were
performed to investigate the kinetics of fibronectin (FN)
and its clinical significance in bronchial asthma.
 
Methods:
 
Measurements of plasma fibronectin (PFN)
and sputum fibronectin (SFN) were performed in asth-
matic patients. Eosinophil chemotaxis, adherence and
activation activity to FN were measured. An animal
model of bronchial asthma was created and lung tissues
were analyzed by immunohistochemical staining.
 
Results:
 
Compared with periods without an asthmatic
attack, the PFN level was significantly lower during
periods with more severe asthmatic attacks in 15
patients with bronchial asthma. In contrast, the SFN
level was significantly higher during periods with more
severe asthmatic attacks. In a guinea pig model of
asthmatic bronchitis, FN was positively stained in the
subepithelial or submucosal tissue and abraded epi-
thelial cells in the alveolar space during asthmatic
attacks. Marked eosinophilic infiltration was also
noted in the same tissues and cells. A negative cor-
relation was noted between the number of peripheral
eosinophils and the PFN level. In contrast, a positive
correlation was noted between the number of sputum
eosinophils, which reflects the severity of asthmatic
attacks, and the SFN level. An experimental study was
performed to investigate the relationship between
eosinophils and FN. A positive relationship was noted
between eosiophil chemotaxis, increased adherence
of activated eosinophils and FN levels.
 
Conclusions:
 
It is suggested that FN may enhance
allergic reactions at an early or acute phase of bron-
chial asthma.
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I
 
NTRODUCTION
 
Bronchial asthma has been recognized as an airway
inflammation associated with damage in the mucosal
epithelium caused by a restricted air flow, airway hyper-
sensitivity and infiltration of inflammatory cells, including
eosiophils.
Eosinophils, effector cells in bronchial asthma,
migrate from blood vessels to the airway, accumulate
and adhere to the local site of asthmatic reactions.
Airway inflammation is induced by chemical mediators,
such as leukotrienes, released from eosinophils activated
by antigens. In the process of inflammation, tissue
damage is caused by cytotoxic intragranular proteins,
including eosinophilic cationic protein (ECP). Although
the types of inflammatory cells involved are different, the
process of inflammation is similar between bronchial
asthma and pneumonia, in which neutrophils are the
effector cells. Fibronectin (FN) has attracted attention as
an important cell adhesive protein in acute pulmonary
inflammation with respect to the migration, accumulation
and adhesion of effector cells to the reaction site.
 
1
 
 It has
been reported that FN has a close relationship with
fibrous tissue formation in pulmonary fibrosis,
 
2
 
 tumor cell
invasion in lung cancer
 
3
 
 and inhibition of inflammatory
processes and tissue repair in pneumonia.
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Based on the assumption that bronchial asthma is an
eosinophil-dominant inflammatory disease of the lung,
it was speculated that FN plays a similar role in the
development of bronchial asthma as in the development
of pneumonia. Clinical and experimental studies were
performed to clarify the role of FN in bronchial asthma.
 
M
 
ETHODS
 
Clinical study
 
Subjects
 
The subjects of the present study consisted of 15 patients
with bronchial asthma fulfillling the following four cri-
teria: (i) no complication of other chronic obstructive
lung diseases suggested by clinical findings or diag-
nostic imaging; (ii) detectable airway hypersensitivity on
the Astograph (Chest Co., Tokyo, Japan); (iii) a good
response to inhaled bronchodilators (> 20% increase in
forced expiratory volume in 1 s (FEV
 
1
 
) compared with the
value during an asthma attack); and (iv) adequate
follow-up data of the clinical course. Ten healthy volun-
teers were also included in the study as a control group.
Informed consent was obtained from each subject and
written in the clinical record.
Respiratory function tests were performed at each visit
to the out-patient clinic for each subject. Based on the
FEV
 
1
 
 value after the inhalation of bronchodilators,
the pulmonary condition was classified as follows: (i) the
non-attack state (no stridor and a <10% decrease in
FEV
 
1
 
 compared with the best value); (ii) a mild attack
(notable stridor and an 11–20% decrease in FEV
 
1
 
 com-
pared with the best value); or (iii) a moderate attack
(notable stridor and a 21–30% decrease in FEV
 
1
 
 com-
pared with the best value). Plasma and sputum FN (PFN
and SFN, respectively) were measured for each pul-
monary condition. The severity of asthmatic attacks was
evaluated using the severity classification made by the
Japanese Society of Allergology.
 
4
 
All patients had taken long-acting theophylline tablets
(400 mg daily), inhaled fluticasone propionate (400 
 
µ
 
g
daily) and inhaled 
 
β
 
2
 
-adrenergic receptor agonists on
demand.
 
Measurement of PFN and SFN
 
PFN measurement
 
Blood samples (2 mL) were collected
in tubes containing EDTA. The plasma fraction was
separated and stored at –70
 
°
 
C.
 
SFN measurement
 
After a 5 min inhalation of 3%
physiological saline (5 mL) via a glass jet nebulizer
connected to a compressor, a sample of induced
sputum was taken in a plate and stored at 4
 
°
 
C. Within
6 h after collection, according to the method of Gleich
 
et al
 
.,
 
5
 
 the sputum sample, after removal of salivary
components, was added to 10 mL physiological saline,
mixed for 1 min on a vortex mixer and centrifuged at
40 000 
 
g
 
 for 30 min at 4
 
°
 
C. The clear supernatants
obtained were added to protamine sulfate at 1/10
volume to prevent collapse of eosinophils and stored
at –70
 
°
 
C. Frozen samples of the plasma and sputum
were thawed at room temperature for the measurement
of PFN and SFN. Using a human FN measurement
kit (Boehringer Mannheim, Mannheim, Germany) for
immunoturbidimetric assay, anti-FN antibody solution
(0.1 mL) was added to the samples. Extinction (E) was
measured 1 and 11 min after the addition of anti-FN
antibody (E1 and E11, respectively) to yeild E = E2 – E1.
The concentration of FN in each sample was determined
using a test curve made with FN standard solutions in
the kit. The extinction measurement was performed
at 340 nm using a double-beam spectrophotometer
(model 100-60; Hitachi, Tokyo, Japan).
 
Eosinophil counts in the sputum
 
After the above-mentioned treatment, sputum specimens
were fixed on a microscope slide, stained according to
the Litt method and observed under a microscope at a
magnification of 
 
×
 
400. The mean number of eosinophils
in 10 microscopic fields was obtained and used for
analysis.
 
Separation of eosinophils from human blood
 
Eosinophils were separated from blood samples using
the density gradient centrifugation of Nycodenz.
 
6
 
 To
each heparinized (10 U heparin/mL blood) venous
blood sample (20 mL), 5 mL of a 6% dextran physio-
logical saline solution was added and the mixture
allowed to stand for 60 min at room temperature. After
removing the white blood cell (WBC) supernatant,
Hanks’ balanced salt solution (BSS; pH 7.2; 10 mL) was
added to the sample and washed for 10 min. This
procedure was repeated twice. The WBC supernatant
obtained was again floated in Hanks’ BSS (2 mL). Using
a 27.6% (w/v) Nycodenz solution (Daiichi Pharma-
ceutical, Tokyo, Japan) and 0.75% NaCl diluent, density
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gradients of 1.116 (75%), 1.102 (63%), 1.094 (56%),
1.086 (50%), 1.081 (46%) and 1.076 g/mL (42%) were
created. A 1.5 mL solution of each density was layered,
from the highest to the lowest density, in a poly-
carbonate tube and allowed to stand at low temperature
to create a non-continuous Nycodenz density gradient
solution. The WBC supernatant (1.5 mL) was super-
posed in the Nycodenz solution and centrifuged at
2400 
 
g
 
 for 20 min at 20
 
°
 
C. An eosinophil-floating
sample was obtained from the cellular fraction of each
density layer, beginning at the lowest layer and proceed-
ing to higher layers.
 
Eosinophil chemotaxis to FN
 
Chemotactic activities of eosinophils to FN were meas-
ured using a modified Boyden chamber (B10-RAD
Ieda, Tokyo, Japan) method.
 
7
 
 Eosinophils were col-
lected using the above-mentioned method and adjusted
to 1 
 
×
 
 10
 
6
 
 cells/mL with a carbonate buffer solution.
Platelet-activating factor (PAF) was used as a control.
Platelet-activating factor generally induces a strong
chemotactic reaction of eosinophils. A preliminary study
was performed to establish the optimal concentration of
PAF for the induction of eosinophil chemotaxis. As a
result, the maximum chemotactic activity of eosinophils
under the present experimental conditions was obtained
at a concentration of 1 
 
×
 
 10
 
–6
 
 mol/L PAF over the range
1 
 
×
 
 10
 
–8
 
 to 1 
 
×
 
 10
 
–2
 
 mol/L. This concentration of PAF
was used as a control in the following study. The
concentration of FN was adjusted to 25, 50, 75 and
100 
 
µ
 
g/mL with a carbonate buffer solution. Using a
blind-well-type chemotactic chamber, the chemotactic
activity of eosinophils induced by each concentration of
FN was measured as follows. Adjusted FN and PAF
solutions (0.25 mL each) were injected into the lower
compartment. After covering the lower compartment
with a polycarbonate membrane filter (diameter 13 mm;
pore size 5 
 
µ
 
m), an eosinophil-floating solution of
0.75 mL was injected into the upper compartment. The
chamber was kept in an incubator (37
 
°
 
C, 5% CO
 
2
 
atmosphere) for 60 min. Then, the filter was removed
from the chamber. The upper surface of the filter was
washed with Hanks’ BSS for cell removal, fixed with
methanol for 12 h, stained according to the Litt method
and observed under a microscope at a magnification of
 
×
 
400. The mean number of eosinophils in 10 micro-
scopic fields was used as the number of chemotactic
eosinophils.
 
Eosinophil adherence to FN
 
Human blood eosinophils were separated using the
above-mentioned Nycodenz
 
6
 
 density gradient centrifu-
gation and adjusted to 1 
 
×
 
 10
 
6
 
 cells/mL with Hanks’ BSS
(pH 7.2). The adhesive activity of activated and non-
activated human blood eosinophils to FN was measured
separately. In order to obtain activated eosinophils,
human serum (1.5 mL) was added to 30 mg zymosan
(Sigma, St Louis, MO, USA), reacted for 60 min at 37
 
°
 
C
and centrifuged at 1000 
 
g
 
 for 5 min. The supernatant
obtained was used as zymosan-activated serum. The
reaction was terminated by heating at 56
 
°
 
C for 30 min.
The zymosan-activated serum was diluted to a concen-
tration of 10% with Hanks’ BSS (pH 7.2). This solution
(2.5 mL) was mixed with an adjusted eosinophil-floating
solution (2.5 mL) and reacted at 37
 
°
 
C for 60 min to
obtain activated eosinophils. In contrast, human serum
(2.5 mL) that had been inactivated by heating at 56
 
°
 
C
for 30 min was mixed with an adjusted eosinophil-
floating solution (2.5 mL) and reacted for 60 min at
37
 
°
 
C to obtain non-activated eosinophils.
A 200 
 
µ
 
g/mL FN solution (0.5 mL), diluted with
carbonate buffer (pH 7.4), was injected into each well of
a tissue culture plate (well diameter 2.4 cm; Corning
Asahi Technoplasa, Tokyo, Japan) and kept at room tem-
perature for 12 h (FN-coated wells). The inner surface of
the wells was washed twice with Hanks’ BSS (pH 7.2).
Activated or non-activated eosinophil solution (0.5 mL)
was injected into each well and reacted under shaking at
37
 
°
 
C for 30 min. After termination of the reaction, the
eosinophil-floating solution in the wells was collected
and washed twice with Hanks’ BSS (pH 7.2). Next, the
reaction was terminated by adding 10% human albumin
(0.5 mL) to an FN-uncoated well, into which 0.05%
trypsin (0.5 mL) and 1 mmol/L EDTA (0.5 mL) had been
injected. Eosinophils adherent to the well surface were
detached and washed twice with Hanks’ BSS (pH 7.2).
The number of floating or adherent eosinophils per
1 mL of each solution was counted on a hemocytometer
using a Unopette (Vect Co., Franklin Lakes, NJ, USA).
The adhesion rate was calculated using the following
equation:
 
        Adhesion rate = (no. adhesive eosinophils  
 
×
 
100
(no. adhesive eosinophils  +  no. floating eosinophils))
 
As a control, the eosinophil adhesion rate was
obtained using the same measurement method except
with carbonate buffer (pH 7.4) in place of FN.
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Activation activity of eosinophils to FN
 
Human blood eosinophils were separated using the
previously mentioned Nycodenz
 
6
 
 density gradient cen-
trifugation and adjusted to 1 
 
×
 
 10
 
6
 
 cells/mL with
Hanks’ BSS (pH 7.2). An eosinophil-floating solution
was injected into a series of tissue culture wells (diameter
2.4 cm) and either 0.5 mL of 50, 100 or 200 
 
µ
 
g/mL
FN-containing carbonate buffer (pH 7.4) was added to
the wells or the same volume of carbonate buffer
(pH 7.4) without FN was added to the wells to serve as
a control. An eosinophil-floating solution (non-activated
eosinophils; 0.5 mL) adjusted to 1 
 
×
 
 10
 
6
 
 cells/mL was
then injected into each well. Activated eosinophil-
floating solution (0.5 mL), which had been prepared
according to the method detailed earlier, was similarly
injected into another series of tissue culture wells and
cultured in an incubator (37
 
°
 
C, 5% CO
 
2
 
 atmosphere)
for 12 h. To differentiate activated eosinophils from
non-activated eosinophils, cells were stained with eosino-
philic granule (EG) 1 and EG2. Based on the affinity of
secretory ECP in eosinophilic granules, EG2-positive
cells were considered to be activated eosinophils.
 
8
 
 The
EG1 and EG2 solutions (Pharmacia Diagnostic, Tokyo,
Japan) were diluted 150- and 300-fold, respectively,
with a 0.1% bovine serum albumin (BSA) solution in
phosphate-buffered saline (PBS; 10 mg BSA in 10 mL
PBS). The diluted EG1 and EG2 solutions (0.5 mL) were
added to each eosinophil sample, along with 0.2 mL
normal serum (10 mL PBS + three drops normal horse
serum), blocked against non-specific reactions to the
secondary antibody and reacted for 24 h at 4
 
°
 
C. After
termination of the reaction, each sample was washed
three times with 5 mL of 0.1 mol/L PBS (pH 7.2) for
5 min, 0.5 mL secondary antibody (1 mL of 0.1 mol/L
PBS (pH 7.2) + antimouse IgG) was added and the
sample was reacted for 30 min at room temperature.
After 30 min, samples were washed and the avidin–
biotin–peroxidase complex (ABC; Vector Laboratories,
Burlingame, CA, USA) was added and reacted for
30 min at room temperature, following by washing and
another reaction in 50 mg 3,3
 
′
 
-diaminobenzidine tetra-
hydrochloride (DAB; Vector), dissolved in 150 mL of
0.1 mol/L Tris-HCl buffer (pH 7.2), for 5 min. Then,
1 mL of 30% H
 
2
 
O
 
2
 
 was added to the samples and
samples were reacted for 5 min, followed by washing
with water for 10 min to terminate the reaction. After
Gill’s hematoxylin staining and Litt staining, samples
were encapsulated and observed under a microscope at
a magnification of 
 
×
 
400. The mean number of EG1-
and EG2-positive eosinophils in 10 microscopic fields
was determined. The eosinophil activation rate was
calculated using the following equation:
 
  Eosinophil activation rate  =  (no. EG2-positive eosinophils 
 
×
 
 100
(no. EG1-positive eosinophils  +  no. EG2-positive eosinophils))
 
Experimental study
 
Creation of an animal model of bronchial asthma
 
A partly modified method of Hoshino 
 
et al.
 
9
 
 was used
to induce active sensitization of the airway with oval-
bumin (OVA; Grade III; Sigma) in male Hartley guinea
pigs weighing between 300 and 400 g. Spontaneous
inhalation of 1% OVA was administered for 10 min
over 10 consecutive days via an ultrasonic nebulizer
(3.0 mL/min; Omron, Tokyo, Japan). The sensitization
was repeated three times at intervals of 7 days. Animals
were then exposed to 1% OVA 1 week after the sensiti-
zation. In order to inactivate histamine H
 
1
 
 receptors,
intraperitoneal injections of 5 mg mepyramine maleate
(Sigma, St Louis, MO, USA) were administered 30 min
before OVA exposure.
The trachea was exposed under general anesthesia
with pentobarbital (30 mg/kg, i.p.). After endotracheal
intubation, mandatory ventilation was performed using a
respirator (model 683; Harvard Apparatus, Millis, MA,
USA) with a tidal volume of 10 mL/kg and a respiratory
rate of 60/min. Endotracheal pressure was monitored
using a differential pressure transducer (TP603T; Nihon
Koden, Tokyo, Japan). Physiological saline was infused
at a rate of 10 mL/kg per h via a catheter inserted into the
jugular vein (Fig. 1).
 
Immunohistological evaluation
 
To observe the localization and stainability of FN in the
sensitized airway, animals were killed by exsanguination
just after OVA exposure. The lung was extirpated, fixed
with formalin and embedded in paraffin. Thin sections
were stained with the ABC method.
 
10
 
 The reaction of
endogenous peroxidase was inhibited by 3% H
 
2
 
O
 
2
 
,
whereas non-specific reactions were inhibited by normal
rabbit serum. Goat antiguinea pig FN (Carbiochem
Bearing) was reacted as a primary antibody and rabbit
antigoat immunoglobulin was used as a secondary
antibody for cross-linkage. After the reaction with ABC
solution (Vectastain, ABC Kit, PK-400; Vector Labora-
tories), coloring was performed with DAB. After contrast
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nuclear staining with hematoxylin, lung sections were
observed under a light microscope. To examine the
localization and stainability of FN, lung sections from
nearly the same site were stained according to the Litt
method and observed under a light microscope.
 
Statistical analysis
 
Data are expressed as the mean 
 
±
 
 SD. Student’s paired
 
t
 
-test was used to evaluate differences between experi-
mental data from different groups. 
 
P
 
 < 0.05 was taken
to indicate statistical significance. Correlation coeffici-
ents between groups were analyzed using the least-
squares method.
 
R
 
ESULTS
 
Clinical study
 
Changes in PFN levels in patients with bronchial 
asthma
 
The PFN level in normal volunteers ranged between 270
and 440 
 
µ
 
g/mL (mean 360 
 
±
 
 82 
 
µ
 
g/mL; Fig. 2). The
PFN level was 225–443 
 
µ
 
g/mL (mean 312 
 
±
 
 52 µg/mL)
during the non-attack state, 150–435 µg/mL (mean
275 ± 71 µg/mL) during a mild asthma attack and
85–325 µg/mL (mean 199 ± 62 µg/mL) during a mod-
erate asthma attack in patients with bronchial asthma.
Fig. 1 Creation of an animal model of bronchial asthma. A guinea pig model of bronchial asthma was created by exposing guinea
pigs to ovalbumin (OVA) after inducing active sensitization of the airway with OVA. The presence or absence of attacks was deter-
mined by an increase in endotracheal pressure.
Fig. 2 Changes in plasma fibronectin (PFN) levels in patients
with bronchial asthma during the non-attack state and during
mild and moderate asthma attacks. Data are the mean ± SD.
The control group consisted of healthy volunteers. Compared
with the control group, the PFN levels tended to be lower during
the non-attack state and during a mild attack, although no sig-
nificant differences were noted between the three groups. The
PFN level was significantly lower during a moderate attack com-
pared with the non-attack state or during a mild attack
(*P < 0.01, **P < 0.01).
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There was no difference between PFN levels in normal
volunteers and those in asthmatic patients during the
non-attack state. The PFN level tended to be lower
during a mild attack compared with the non-attack state.
However, the PFN level was significantly lower during a
moderate attack than during the non-attack state or
during a mild attack in patients with bronchial asthma
(P < 0.01).
Changes in SFN level in patients with bronchial 
asthma
The SFN level in normal volunteers ranged between
0  and 48 µg/mL (mean 16 ± 10 µg/mL; Fig. 3). The
SFN level was 0–78 µg/mL (mean 34 ± 16 µg/mL)
during the non-attack state, 0–99 µg/mL (mean 41 ±
22 µg/mL) during a mild attack state and 12–150 µg/
mL (mean 98 ± 31 µg/mL) during a moderate attack in
patients with bronchial asthma. The SFN value tended to
be higher during the non-attack state and during a mild
attack in patients with bronchial asthma compared with
Fig. 3 Changes in sputum fibronectin (SFN) levels in patients
with bronchial asthma during the non-attack state and during
mild and moderate asthma attacks. Data are the mean ± SD.
The control group consisted of healthy volunteers. Compared
with the control group, the SFN levels tended to be higher
during the non-attack state and during a mild asthma attack,
although no significant differences were noted between the
three groups. The SFN level was significantly higher during a
moderate attack compared with the non-attack state or during
a mild attack (*P < 0.01, **P < 0.05).
Fig. 4 Relationship between plasma fibronectin (PFN) levels
and peripheral eosinophil counts in patients with bronchial
asthma (n = 60). The PFN levels tended to be lower in patients
with a higher absolute number of eosinophils in the peripheral
blood (r = –0.6). Asthmatic attacks tended to be more severe in
patients with a higher absolute number of eosinophils in the
peripheral blood.
Fig. 5 Relationship between sputum fibronectin (SFN) and
sputum eosinophil counts in patients with bronchial asthma
(n = 25). The SFN levels tended to be higher in patients with a
higher absolute number of eosinophils in the sputum (r = 0.7).
Asthmatic attacks tended to be more severe in patients with a
higher absolute number of sputum eosinophils.
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normal volunteers, although no significant differences
were noted. However, the SFN level was significantly
higher during a moderate attack than during the non-
attack state or during a mild attack in patients with
bronchial asthma (P < 0.01 and P < 0.05, respectively).
Relationship between PFN levels and peripheral 
eosinophil count
The PFN level tended to be lower in patients with a
higher absolute number of eosinophils in the peripheral
blood (r = –0.6; Fig. 4). Asthmatic attacks tended to be
more severe in patients with a higher absolute number of
eosinophils in the peripheral blood.
Relationship between SFN and sputum eosinophil 
count
The SFN level tended to be higher in patients with a
higher absolute number of eosinophils in the sputum
(r = 0.7; Fig. 5). Asthmatic attacks tended to be more
severe in patients with a higher absolute number of
sputum eosinophils. However, eosinophils were not
observed in the sputum in 10 patients during an asth-
matic attack. One possible explanation for this is that
a sufficient quantity of sputum may not have been
obtained from the sites responsible for asthmatic attacks
on only two evoked sputum tests.
Eosinophil chemotaxis induced by FN
The number of migration eosinophils was 29–54 cells/
high-power field (h.p.f.; mean 41 ± 8 cells/h.p.f.) for FN
at 50 µg/mL, which was similar to 32–58 cells/h.p.f.
(mean 44 ± 9 cells/h.p.f.) for 10–6 mol/L PAF used as a
control (Fig. 6). The number of migrating eosinophils
was 24 ± 6, 31 ± 6 and 18 ± 7 cells/h.p.f. for 25, 75
and 100 µg/mL FN, respectively. Compared with PAF,
the chemotactic activity of these concentrations of FN
were lower.
Fig. 6 Eosinophil chemotaxis induced by fibronectin (FN) at
concentrations of 25, 50, 75 and 100 µg/mL. Data are the
mean ± SD. The number of eosinophils was adjusted to
1 × 106 cells/mL. Compared with platelet-activating factor
(PAF) as a control, 50 µg/mL FN induced an equivalent chemo-
tactic activity of eosinophils. However, the eosinophil chemo-
taxis induced by 25, 75 and 100 µg/mL FN was mild.
Fig. 7 Experimental method for detecting eosinophil (Eo.)
adherence to fibronectin (FN; 200 µg/mL). The number of
eosinophils was adjusted to 1 × 106 cells/mL. Activated or
non-activated eosinophils were injected into FN-coated wells.
The adherence of eosinophils was calculated using the equation
given at the bottom of the figure. BSA, bovine serum albumin;
EG1, EG2, eosinophilic granule 1 and 2, respectively; ABC,
avidin–biotin–peroxidase complex; DAB, 3,3′-diaminobenzi-
dine tetrahydrochloride.
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Eosinophil adherence to FN
The adherence of non-activated eosinophils to FN was
12–31% (mean 21.1 ± 5.4%) in FN-uncoated wells
and 18–39% (mean 26.6 ± 3.5%) in FN-coated wells
(Figs 7,8). No significant difference was noted between
the two groups. In contrast, the adherence of activated
eosinophils to FN was 54–69% (mean 59.3 ± 3.4%) in
FN-coated wells, which was significantly higher than the
27–42% (mean 34.2 ± 5.1%) in FN-uncoated wells
(P < 0.01). There were no significant differences in
adherence between activated eosinophils in FN-coated
wells and non-activated eosinophils in FN-coated and
-uncoated wells.
Activation of eosinophils to FN
Activated eosinophils were observed at a frequency of
3–19% (mean 11 ± 7%) in the control state, 12–20%
(mean 15 ± 4%) with 50 µg/mL FN, 25–34% (mean
29 ± 3%) with 100 µg/mL FN and 25–33% (mean
28 ± 3%) with 200 µg/mL FN (Figs 9,10). Compared
with control, activated eosinophils were significantly
higher following the addition of 100 and 200 µg/mL FN
(P < 0.05).
Histological study
Non-attack state
There was no stenosis or eosinophilic infiltration in the
airway (Litt staining; Figs 11,12). Slight localization of
FN was observed in the basement membrane of the
bronchial epithelium and stroma (enzyme-labeled anti-
body method).
Asthmatic attack
Severe stenosis of the airway, marked eosinophilic infil-
tration in the submucosal space and partial epithelial
abrasion were noted (Litt staining; Figs 13,14). Com-
pared with the non-attack state, marked localization of
FN was observed in the proliferated connective tissue in
the submucosal area, abraded epithelium and sub-
epithelial space (enzyme-labeled antibody method).
Fig. 9 Experimental method for detecting activation activity of
eosinophils (Eo.) to 50, 100 and 200 µg/mL fibronectin
(FN).The number of eosinophils was adjusted to 1 × 106 cells/
mL. Non-activated eosinophils were added to wells after the
wells had been coated with 50, 100 or 200 µg/mL FN, reacted
and were stained with eosinophilic granule (EG) 1 and EG2.
The EG2-positive cells were defined as activated eosinophils.
The eosinophil activation rate was calculated by the equation at
the bottom of the figure.
Fig. 8 Adherence of activated and non-activated eosinophils
to 200 µg/mL fibronectin (FN). Data are the mean ± SD. The
number of eosinophils was adjusted to 1 × 106 cells/mL. No
significant increase was noted in the adherence of non-activated
eosinophils to FN. In contrast, the adherence of activated eosino-
phils is significantly higher than that of non-activated
eosinophils (*P < 0.01, **P < 0.01). The adherence of acti-
vated eosinophils tended to increase in FN-coated wells
(FN(+)); FN(–), FN-uncoated wells.
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DISCUSSION
Kinetics of FN
As a possible explanation for the decrease in PFN under
various conditions, Saba et al.11 suggested that severe
trauma and burns increase local consumption of FN,
Fig. 10 Activation activity of eosinophils to 50, 100 and
200 µg/mL fibronectin (FN). Data are the mean ± SD. The
number of eosinophils was adjusted to 1 × 106 cells/mL. Com-
pared with the control state, the activation activity of eosinophils
did not change significantly with 50 µg/mL FN. However,
activity increased significantly with 100 and 200 µg/mL FN
(*P < 0.05, **P < 0.05).
Fig. 11 Control (non-attack) state: neither eosinophils nor
bronchospasm was found (Litt stain; original magnification
×400).
Fig. 12 Control (non-attack) state: slight localization of
fibronectin (brown) was found in bronchial basement mem-
brane and alveolar interstitium (avidin–biotin–peroxidase
complex method; original magnification ×400).
Fig. 13 Asthma attack: marked eosinophil infiltration in bron-
chial wall, dominant bronchospasm and destroyed epithelium
are observed (Litt stain; original magnification ×400).
Fig. 14 Asthma attack: marked deposition of fibronectin on
the inner and outer sides of the bronchial wall is observed (avidin–
biotin–peroxidase complex method; original magnification ×400).
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which mediates macrophage clearance of particulates,
such as degenerative and destructive cells. Kawai et al.12
reported that the decrease in PFN was attributable to the
inhibition of FN production due to extended damage of
vascular endothelial cells, the FN synthesizing site, in
septic adult respiratory distress syndrome (ARDS).
Oshitani1 reported that local accumulation of FN
was increased to achieve neutrophilic inhibition
against inflammatory changes in pneumonia. Scott
et al.13 reported that FN synthesis was inhibited in severe
nutritional disorders. However, there have been no
reports on the etiology of significant decreases in PFN in
bronchial asthma, especially more marked decreases
during severe attacks. The present study showed that FN
staining increased in the airway mucosa during asth-
matic attacks in the guinea pig experimental model of
bronchial asthma. Therefore, it was considered that the
decrease in PFN was attributable to increased local
consumption of FN during attacks. In contrast with the
decrease in PFN, the SFN level increased significantly
during asthmatic attacks. To explain this phenomenon,
precise information on airway pathology is required.
However, it is practically impossible to obtain histo-
logical specimens or bronchoalveolar lavage fluid
(BALF) during asthmatic attacks. In the present study,
sputum was given an important factor expressing airway
condition.
Sputum samples were collected after inhalation of 3%
physiological saline according to the method of Do et al.5
As a result, compared with the non-attack state, the SFN
level increased significantly during mild and moderate
attacks. The increase was more marked during attacks
with a greater severtiy. It is evident that FN increases in
the inflammation site of the airway. Combined with the
decrease in PFN during attacks, the results indicate that
FN should migrate from the blood to the airway during
asthmatic attacks or that the production of FN should be
enhanced in the airway, probably by fibroblasts. The pro-
duction of FN in the airway is induced by fibroblasts,
which migrate and proliferate in the airway after activa-
tion by cytokines with fibrogenic and smooth muscle pro-
liferative activities, such as transforming growth factor
(TGF)-α, TGF-β and platelet-derived growth factor.14 It
has been reported that FN is also produced in epithelial
cells in the airway.15 Remodeling is considered to play an
important role in the development of airway stenosis in
bronchial asthma. Remodeling of the airway indicates the
repair process of tissue damage and associated wall
thickening of the airway.16 The thickening is caused by
accumulation of extracellular matrix consisting of fibro-
blasts, collagen types I, III and V and FN.15,17 Based on
the pathogenesis of bronchial asthma, changes in PFN
and SFN levels during asthmatic attacks can be explained
as follows. Plasma FN decreased because FN was mobi-
lized and consumed in the airway, not only as a chemo-
tactic factor of eosinophils, but also as a retaining or
adhesive factor of eosinophils at the inflammatory site of
the airway. In contrast, SFN increased because FN was
transferred from the blood to the airway.
Relationship between FN and eosinophils in 
bronchial asthma
In the latter part of this study, the relationship between
PFN levels and eosinophil counts in the peripheral
blood was observed. As a result, a negative correlation
(r = –0.6) was found between the two variables,
although a slight deviation was noted. The eosinophil
count tended to be higher according to the severity of
the attacks. Moreover, peripheral eosinophils tended to
increase with a decrease in PFN levels. In contrast,
eosinophils in the sputum and the SFN level tended to
increase during more severe attacks. A positive cor-
relation was found between the number of sputum
eosinophils and the SFN level (r = 0.7). Therefore, a
kind of interaction should exist between eosinophils and
FN in the blood and sputum. To closely examine the
interaction between eosinophils and FN, an in vitro study
was performed. Eosinophils in the peripheral blood
should migrate into the airway before the induction of
eosinophilic inflammation. The extravascular migration
of eosinophils may require adhesion to vascular
endothelial cells and transmigration through the intra-
cellular space of the vascular endothelium. Adhesive
molecules activated and expressed on the membrane
surface of eosinophils and vascular endothelial cells
play an important role in this processes.18,19 Springer20
reported that lymphocyte function-associated antigen
(LFA-1) and complement receptor type 3 (CR3) on the
membrane surface of eosinophils and intercellular adhe-
sion molecule-1 (ICAM-1), very late antigen-4 (VLA-4)
and vascular cell adhesion molecule-1 on vascular
endothelial cells were especially important. Springer20
also reported that conjugation of LFA-1 and CR3 on the
membrane surface of eosinophils and ICAM-1 on vas-
cular endothelial cells played an important role in the
transmigration process of eosinophils through the intra-
cellular space of the vascular endothelium. Swerlick
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et al.21 suggested that FN regulates the expression of
CR3 and VLA-4 on the membrane surface of eosin-
ophils. Anwar et al.22 reported that FN prolonged the
survival of eosinophils in culture. The present study
showed that FN, at a concentration of 50 µg/mL,
induced strong chemotactic activity of eosinophils
equivalent to PAF. It was suggested that FN played an
important role in the migration of eosinophils. In the
present experimental study using a guinea pig model of
bronchial asthma, marked eosinophilic infiltration was
noted in the subepithelial or submucosal spaces in the
lung with airway narrowing. Marked FN stainability was
observed in the same area with an enzyme-labeled
antibody method. Therefore, a direct interaction was
suggested between FN and eosinophils. During asth-
matic attacks, eosinophils were mobilized to the airway
and activated to induce allergic inflammation. The
present study showed that the production of ECP, an
indicator of FN-dependent adherence and activation
of eosinophils, increased during the process of aller-
gic inflammation. Therefore, FN may enhance allergic
reactions at an early or acute phase of bronchial
asthma. Although FN is not considered to be the
major promoter of allergic reactions, FN is definitely
an important factor in the disease process of bron-
chial asthma.
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